Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.72 |
| ▸ | MAOB | P27338 | 1/20 | 0.70 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.67 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9187476 | 0.88 | NR4A2 (0.70) | NR4A2PTPN1MAOBSMPD1SRD5A2 | |
| SCHEMBL7901142 | 0.88 | NR4A2 (0.74) | NR4A2PTPN1MAOBSMPD1SRD5A2 | |
| SCHEMBL28805378 | 0.87 | MAOB (0.74) | NR4A2PTPN1MAOBSMPD1NR1H4 | |
| SCHEMBL27916079 | 0.87 | NR4A2 (0.74) | NR4A2PTPN1MAOBSMPD1MEN1 | |
| SCHEMBL6131764 | 0.86 | PTPN1 (0.79) | NR4A2PTPN1MAOBSMPD1SRD5A2 | |
| SCHEMBL2152475 | 0.86 | MAOB (0.73) | NR4A2PTPN1MAOBSMPD1SRD5A2 | |
| SCHEMBL1438839 | 0.86 | NR4A2 (0.72) | NR4A2PTPN1MAOBSMPD1SRD5A2 | |
| SCHEMBL7337987 | 0.86 | NR4A2 (0.72) | NR4A2PTPN1MAOBSMPD1SRD5A2 | |
| SCHEMBL339009 | 0.85 | NR4A2 (1.00) | NR4A2PTPN1MAOBSMPD1SRD5A2 | |
| SCHEMBL7908051 | 0.85 | SRD5A2 (0.85) | NR4A2PTPN1MAOBSMPD1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107857748-B | 5- [ 2-hydroxy-3- (alkylamino) propoxy ] benzofuran compound and application thereof | 沈阳药科大学 | 2020-06-02 | — | — | CN | claimed |
| CN-107935972-B | 5- [ 2-hydroxy-3- (isopropylamino) propoxy ] benzofuran derivative and application thereof | 沈阳药科大学 | 2020-06-02 | — | — | CN | claimed |
| US-12297176-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4549424-A1 | NEW LITHIUM EXTRACTING AGENT AND LIQUID ORGANIC MIXTURE THEREOF, AND METHOD FOR EXTRACTING LITHIUM BY MEANS OF EXTRACTION | Beijing Salt Lake Technology Development Company Limited (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-117534556-A | Novel lithium extractant, liquid organic mixture thereof and method for extracting lithium by extraction | 北京索特莱克科技发展有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2024027447-A1 | NEW LITHIUM EXTRACTING AGENT AND LIQUID ORGANIC MIXTURE THEREOF, AND METHOD FOR EXTRACTING LITHIUM BY MEANS OF EXTRACTION | 北京索特莱克科技发展有限公司 | 2024-02-08 | — | — | WO | disclosed |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-0391624-A1 | Substituted 1-[3-heteroarylmethoxy)phenyl] alkanols and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0056172-B1 | PHENOXY- AND THIOPHENOXY COMPOUNDS, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | FISONS plc (GB) | 1985-04-03 | — | — | EP | disclosed |
| US-4479007-A | Chroman-4-ones and process for preparing same | BAYER AKTIENGESELLSCHAFT (DE) | 1984-10-23 | — | — | US | disclosed |
| US-4415741-A | REACTING O-HYDROXYACETOPHENONE AND CYCLOPENTANONE | BAYER AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| EP-0056172-A2 | Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them | FISONS plc (GB) | 1982-07-21 | — | — | EP | disclosed |
| US-4307020-A | REACTING AN 0-HYDROXYACETOPHENONE WITH A GLYOXYLIC ACID | BAYER AKTIENGESELLSCHAFT (DE) | 1981-12-22 | — | — | US | disclosed |
| US-4285965-A | FUNGICIDES AND INSECTICIDES FOR PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-25 | — | — | US | disclosed |
| EP-0000377-B1 | PROCESS FOR THE PREPARATION OF CHROMONE DERIVATIVES, NEW CHROMONE DERIVATIVES AND THEIR USE AS PLANT-PROTECTING AGENTS | BAYER AG (DE) | 1981-01-21 | — | — | EP | disclosed |
| US-4189498-A | FUNGICIDES, ARTHROPODICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297176-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | HGF, SMAD3, HRAS | NR4A2 500/4885PTPN1 3234/4885MAOB 4207/4885 |
| US-11078159-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | HGF, SMAD3, HRAS | NR4A2 500/4885PTPN1 3234/4885MAOB 4207/4885 |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | NR4A2 136/4885PTPN1 2235/4885MAOB 1583/4885 |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | HGF, SMAD3, HRAS | NR4A2 500/4885PTPN1 3234/4885MAOB 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.